A comprehensive guide to the ICD-10 code for yeast in urine (B37.49

In the intricate world of clinical microbiology and diagnostic medicine, few findings are as simultaneously common and clinically ambiguous as the presence of yeast in a urine sample. For the patient, it might be an incidental note on a lab report, a cryptic piece of data with unclear implications. For the physician, it is a puzzle—a potential red flag for a serious underlying infection or merely a harmless contaminant from the skin. For the medical coder and health informaticist, it is a specific alphanumeric sequence that must be assigned with precision: ICD-10-CM code B37.49.

This article embarks on a comprehensive exploration of this finding, delving far beyond the simple assignment of a code. We will dissect the clinical significance of candiduria, the pathogenic yeasts responsible, the diagnostic conundrums it presents, and the nuanced therapeutic decisions it demands. The assignment of B37.49 is not a mere administrative task; it is the final, standardized representation of a complex clinical story. It encapsulates a patient’s underlying health status, their vulnerability to opportunistic infections, and the clinical judgment of their healthcare provider. By understanding the depth of information contained within this single code, we can appreciate the critical intersection of laboratory science, clinical practice, and the data-driven infrastructure of modern healthcare. This is more than a code; it is a gateway to understanding a fascinating and clinically significant medical condition.

2. Decoding the Diagnosis: What Does “Yeast in Urine” Really Mean?

The term “yeast” in a clinical context most often refers to a group of fungi that reproduce by budding. In the environment of the human urinary tract, this almost invariably points to organisms belonging to the genus Candida.

Candida Species: The Principal Culprits

Candida is a commensal organism, meaning it naturally resides on and within the human body without causing harm in healthy individuals. It is commonly found in the gastrointestinal tract, the oral cavity, the vagina, and on the skin. The most prevalent species by far is Candida albicans, accounting for a majority of clinical isolates. However, the epidemiological landscape is shifting, with an increasing incidence of non-albicans species such as:

• Candida glabrata: Noted for its potential reduced susceptibility to azole antifungals.

• Candida tropicalis: Often associated with more invasive disease in immunocompromised hosts.

• Candida parapsilosis: Commonly associated with biofilm formation on medical devices.

• Candida krusei: Intrinsically resistant to fluconazole, a first-line antifungal.

The transition of Candida from a harmless commensal to a potential pathogen is a key concept. This occurs when there is a disruption in the host’s defense mechanisms, allowing the yeast to proliferate and invade.

The Spectrum of Candiduria: From Contamination to Crisis

The finding of yeast in urine, or candiduria, exists on a wide clinical spectrum:

1. Contamination: The most common scenario, especially in voided samples from women. Yeast from the periurethral area or vagina can easily be introduced into the urine specimen during collection, representing no true infection of the urinary tract.

2. Asymptomatic Candiduria: The presence of a significant quantity of yeast in the urine (>10,000 to 15,000 colony-forming units per milliliter) in a patient with no symptoms referable to the urinary tract. This is often a colonization of the bladder or an indwelling catheter.

3. Symptomatic Candiduria (Candidal Cystitis): An actual infection of the bladder causing symptoms such as urinary frequency, urgency, dysuria (painful urination), and suprapubic pain.

4. Ascending Infection (Candidal Pyelonephritis): A more serious infection where the yeast ascends from the bladder to the kidneys, causing fever, chills, flank pain, and potentially leading to renal impairment.

5. Fungal Ball (Bezoar): A rare but severe complication where a mass of fungal hyphae, yeast cells, and debris forms in the renal pelvis or bladder, potentially causing obstruction and irreversible kidney damage.

Understanding where a patient falls on this spectrum is the fundamental challenge for the clinician and directly influences the accuracy of the assigned ICD-10 code.

3. The Critical Role of ICD-10 Coding in Modern Healthcare

The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) is the standard system used in the United States to classify and code all diagnoses, symptoms, and procedures. While its function in medical billing and reimbursement is well-known, its importance extends much further.

Beyond Billing: The Power of a Code

A correctly assigned ICD-10 code like B37.49 is a critical data point that fuels numerous aspects of healthcare:

• Epidemiology and Public Health: Aggregated codes allow health authorities to track the incidence and prevalence of diseases, such as identifying outbreaks of drug-resistant Candida strains in a hospital or region.

• Clinical Research: Researchers use coded data to identify patient populations for studies, track outcomes of different treatment regimens for candiduria, and investigate risk factors.

• Quality Assurance and Patient Safety: Hospitals analyze coding data to monitor rates of hospital-acquired infections (like catheter-associated urinary tract infections involving Candida) and implement quality improvement initiatives.

• Resource Allocation and Planning: Public health planning and resource allocation for antifungal medications and diagnostic tools can be informed by trends revealed through coded data.

• Clinical Decision Support: Electronic health records (EHRs) can use codes to trigger alerts for best-practice advisories, such as recommending catheter removal or a specific antifungal based on local resistance patterns.

Therefore, the precision with which a coder assigns B37.49 directly impacts the quality and utility of this vast healthcare data ecosystem.

4. A Deep Dive into ICD-10-CM Code B37.49: Candidiasis of Other Urogenital Sites

The official ICD-10-CM code for yeast (candidal infection) in the urine is B37.49.

Code Structure and Hierarchy

To fully understand this code, one must parse its structure within the ICD-10-CM hierarchy:

• Chapter I (A00-B99): Certain Infectious and Parasitic Diseases. This places candidiasis firmly within the domain of communicable diseases.

• Block (B35-B49): Mycoses. This specifies it is a fungal disease.

• Category B37: Candidiasis. This is the parent code for all forms of candidal infection.

• B37.4: Candidiasis of other urogenital sites. This subcategory is for urogenital candidiasis not specified elsewhere.

• B37.49: Candidiasis of other urogenital sites. This is the specific code used when the documentation is not more specific.

Why “Other Urogenital Sites” Applies to Urine

At first glance, the description may seem vague. However, the ICD-10-CM index provides clarity. When one looks up “Candidiasis, urinary,” the index directs the coder to B37.49. The code B37.2 is reserved for “Candidiasis of skin and nail,” and B37.3 for “Candidiasis of vulva and vagina.” Since the urinary tract (bladder, ureters, kidneys) is a urogenital site not specified by another code, B37.49 is the appropriate choice.

Exclusions and Differential Diagnoses

It is crucial to understand what B37.49 is not used for. The code should not be assigned if a more specific site is documented.

• B37.41 – Candidal balanitis: Infection of the glans penis.

• B37.42 – Candidal vulvovaginitis: A very common vaginal yeast infection.

• N30.0- / N30.1-: Acute or chronic cystitis. If the provider documents “bacterial cystitis,” a code from this range would be used, not B37.49. However, if it is “candidal cystitis,” B37.49 is correct, as there is no more specific code for the bladder itself.

This highlights the paramount importance of clinical documentation. The coder is entirely dependent on the provider’s precise terminology.

5. Clinical Scenarios and Coding Precision: When to Use B37.49

The application of B37.49 is guided by the physician’s documentation. Let’s explore several common clinical scenarios.

Scenario 1: The Asymptomatic Patient with a Urine Culture Positive for Yeast

• Presentation: An 80-year-old diabetic woman is admitted for heart failure. A routine urinalysis reveals yeast, confirmed by a culture growing >100,000 CFU/mL of Candida albicans. She has no urinary symptoms.

• Clinical Decision: The physician diagnoses “Asymptomatic Candiduria.” Treatment may not be initiated, but the finding is clinically relevant.

• Coding: B37.49 is assigned. This accurately reflects the diagnosed condition.

Scenario 2: Candiduria in the Catheterized Patient

• Presentation: A 65-year-old man in the ICU with a Foley catheter has a urine culture positive for Candida glabrata.

• Clinical Decision: The physician documents “Candiduria, likely catheter-associated.” The primary intervention is catheter removal or change, if possible.

• Coding: B37.49 is assigned for the candiduria. Additionally, a code from T83.51- (Infection and inflammatory reaction due to indwelling urinary catheter) would be assigned as a secondary code to specify the cause.

Scenario 3: Ascending Infection and Fungal Balls

• Presentation: A premature neonate with a long-term urinary catheter develops an obstructing “fungal ball” (bezoar) in the renal pelvis, causing hydronephrosis.

• Clinical Decision: The physician diagnoses “Renal Candidiasis with Fungal Bezoar.”

• Coding: B37.49 is used for the infection. A code for N13.5 (Crossing vessel and stricture of ureter without hydronephrosis) or N13.8 (Other obstructive and reflux uropathy) might be used to represent the obstruction, but the primary infectious diagnosis remains B37.49.

Scenario 4: Differentiating Cystitis from Pyelonephritis

• Presentation: A 40-year-old woman on long-term steroids presents with dysuria, frequency, and suprapubic pain. A culture grows Candida.

• Clinical Decision: The physician diagnoses “Candidal Cystitis.”

• Coding: B37.49 is assigned. There is no separate code for “candidal pyelonephritis”; it would also be coded to B37.49. The clinical severity is captured in the documentation, not the code itself.

6. The Diagnostic Pathway: From Urinalysis to Definitive Culture

Identifying yeast in urine is a multi-step process that moves from screening to confirmation.

The Urinalysis Dipstick and Microscopy

The initial clue often comes from a routine urinalysis. While a dipstick is not specific for yeast, the presence of leukocyte esterase (suggesting white blood cells) and nitrites (typically for bacteria) can indicate an infectious process. The definitive finding on urinalysis is the visualization of budding yeast cells and/or pseudohyphae during microscopic examination. The presence of pseudohyphae (chains of cells) is often a sign of tissue invasion and a more active infection, as seen with C. albicans.

The Gold Standard: Urine Culture and Susceptibility Testing

A urine culture is required for confirmation and speciation. The sample is plated on agar, and after 24-48 hours, creamy, white colonies appear. The microbiology lab can then identify the species (e.g., C. albicans, C. glabrata) and perform antifungal susceptibility testing (AFST) to guide therapy, especially in refractory or systemic infections.

Advanced Diagnostic Tools: PCR and Beta-D-Glucan

In complex cases, molecular methods like Polymerase Chain Reaction (PCR) can provide rapid species identification. The serum (1,3)-β-D-glucan test is a blood test that detects a component of the fungal cell wall and can be a useful marker for invasive fungal infections, though it is not specific to Candida or the urinary tract.

7. At-Risk Populations: Who is Most Vulnerable to Candiduria?

Candiduria rarely occurs in a vacuum. It is almost always a marker of an underlying compromise in the host’s defenses. The following table summarizes the key risk factors.

 Risk Factors for the Development of Candiduria

8. Therapeutic Interventions: To Treat or Not to Treat?

The management of candiduria is one of the most nuanced areas in infectious diseases, hinging on the critical distinction between colonization and true infection.

Antifungal Medications: An Overview

The mainstay of treatment for symptomatic infection is antifungal therapy. Common classes include:

• Azoles (e.g., Fluconazole): First-line for most C. albicans infections. It is well-concentrated in the urine. C. glabrata may have dose-dependent susceptibility, and C. krusei is resistant.

• Echinocandins (e.g., Micafungin, Caspofungin): Reserved for systemic or invasive infections, as they achieve poor concentrations in the urine.

• Polyenes (e.g., Amphotericin B): Potent but toxic. Amphotericin B bladder irrigation can be used for localized bladder infections in selected cases.

Managing Asymptomatic Candiduria

For most patients with asymptomatic candiduria, treatment is NOT recommended. Studies have shown that treating asymptomatic patients does not improve outcomes and can lead to the emergence of resistant organisms. The key interventions are:

1. Remove or change the indwelling catheter.

2. Discontinue unnecessary antibiotics.

3. Optimize glycemic control in diabetics.

Treatment may be considered in a select few high-risk scenarios, such as neutropenic patients or those undergoing urological procedures, where the risk of disseminated infection is high.

Treatment Protocols for Symptomatic Candiduria and Infection

• Candidal Cystitis: Oral fluconazole for 5-7 days is typically effective.

• Candidal Pyelonephritis: Requires longer courses of therapy, often starting with IV fluconazole or, in severe cases, an echinocandin, followed by a step-down to oral therapy.

• Fungal Balls: Often require a combination of systemic antifungal therapy and urological intervention (e.g., percutaneous nephrostomy with irrigation or surgical removal).

9. Prognosis, Complications, and Long-Term Outcomes

The prognosis for candiduria is excellent when it represents asymptomatic colonization or simple cystitis. However, in the context of severe immunosuppression or invasive disease, the outcomes can be guarded. Complications, though rare, can be severe:

• Ascending pyelonephritis leading to renal abscess formation.

• Fungal bezoar causing urinary obstruction and post-obstructive renal failure.

• Candidemia (fungal blood infection), which is a life-threatening condition with high mortality. Candiduria can be a source or a consequence of candidemia.

10. Prevention Strategies: Reducing the Risk of Candiduria

Prevention focuses on mitigating the risk factors outlined in Table 1:

• Judicious use of urinary catheters: Insert only when necessary and remove as soon as possible.

• Antibiotic stewardship: Use the narrowest-spectrum antibiotic for the shortest effective duration.

• Meticulous catheter care: Maintaining a closed drainage system and proper hygiene.

• Glycemic control: Tight blood sugar management in diabetic patients.

• Probiotics: The evidence is mixed, but some studies suggest probiotics (e.g., Lactobacillus) may help restore normal flora and reduce candidal colonization.

11. The Intersection of Microbiology, Clinical Practice, and Health Informatics

The journey of a patient with candiduria beautifully illustrates the synergy between different medical disciplines. The microbiologist identifies the organism; the clinician interprets the finding in the context of the patient and makes a diagnostic and therapeutic decision; and the medical coder translates that clinical narrative into a standardized data point (B37.49). This data point then feeds back into the system, informing public health, research, and quality metrics. Accurate coding is the linchpin that ensures this feedback loop is robust and reliable.

12. Conclusion: The Significance of a Single Code

The finding of yeast in urine, coded as ICD-10-CM B37.49, is a deceptively simple entry that represents a complex clinical entity. It demands a careful synthesis of laboratory data, patient symptoms, and risk factors to distinguish harmless colonization from a potentially serious infection. The code itself is a powerful tool, essential not only for reimbursement but for tracking disease trends, driving research, and improving the quality of patient care. Ultimately, understanding the story behind B37.49 is to understand a critical aspect of modern medical practice where diagnostic acumen, therapeutic nuance, and data integrity converge.

13. Frequently Asked Questions (FAQs)

Q1: I have yeast in my urine but no symptoms. Do I need treatment?
A: In most cases, no. Asymptomatic candiduria is typically a colonization that does not require antifungal medication. The focus should be on addressing underlying risk factors, such as removing an unnecessary catheter. Always follow your doctor’s specific recommendation.

Q2: Can a yeast infection in my urine be passed to my sexual partner?
A: Candiduria itself is not considered a sexually transmitted infection (STI). However, if you have a concurrent vaginal yeast infection (vulvovaginal candidiasis), that can be transmitted to a male partner, who may develop balanitis (inflammation of the penis). It is not typically transmitted through urine.

Q3: What is the difference between a bacterial UTI and a yeast infection in the urine?
A: The causative organism is different. Bacterial UTIs are caused by bacteria like E. coli, while urinary yeast infections are caused by Candida species. The symptoms can be similar (frequency, urgency, pain), but yeast infections are less common and often occur in individuals with specific risk factors. The treatment is also different, requiring antifungals instead of antibiotics.

Q4: Why is my doctor not prescribing medication for the yeast in my urine?
A: This is likely because your doctor has determined it is asymptomatic candiduria. Treating it unnecessarily can lead to side effects from the medication and promote the development of drug-resistant fungi. Their decision is in line with current clinical guidelines.

Q5: Are there dietary changes I can make to prevent candiduria?
A: While a healthy diet supports the immune system, there is no strong scientific evidence that specific diets (like avoiding sugar) can prevent or treat urinary candidiasis. The most effective prevention strategies are medical, such as proper catheter management and antibiotic stewardship.

14. Additional Resources

• Infectious Diseases Society of America (IDSA): Clinical Practice Guidelines for the Management of Candidiasis.

  • Link: https://www.idsociety.org/practice-guideline/candidiasis/

• Centers for Disease Control and Prevention (CDC): ICD-10-CM Official Guidelines for Coding and Reporting.

  • Link: https://www.cdc.gov/nchs/icd/icd-10-cm.htm

• American Urological Association (AUA): Guidelines on Catheter-Associated Urinary Tract Infections.

  • Link: https://www.auanet.org/guidelines/guidelines/cauti-guideline

• National Institutes of Health (NIH) – Genetic and Rare Diseases Information Center: Information on invasive candidiasis.

  • Link: https://rarediseases.info.nih.gov/diseases/10763/invasive-candidiasis

Date: November 06, 2025
Author: Dr. Eleanor Vance, MD, Clinical Microbiology & Health Informatics

Disclaimer: The information contained in this article is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. The coding information provided is for educational purposes and should be verified with the most current official ICD-10-CM coding manuals and guidelines.